Yanshengchao
演生潮
Yanshengchao (演生潮) is a Beijing-based biotech company focused on autoimmune and allergic disease drug development, founded by a team led by Tsinghua University School of Medicine professor Qi Hai . The company's CEO and co-founder is Yifeng Wang . In 2025, Yanshengchao raised a nine-figure RMB Pre-A round co-led by Qiming Venture Partners, YuanSheng Ventures, and Chengdu Technology Innovation Investment Group, with Guosheng Capital as lead organizer , followed later in the year by a nine-figure RMB Series A in which Qiming continued to participate . The company has also disclosed R&D progress updates through its investor Qiming .
AI-generated — may contain errors, please verify.
Coverage
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 45, 2025
Following the milestones of Qiming Venture Partners' portfolio companies, together with you.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 43, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies
Qiming Weekly | Qiming Venture Partners Portfolio Companies: Funding and Updates Vol. 28, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies.
Evolutionary Tide Raises Hundreds of Millions of Yuan in Pre-A Round, Qiming Venture Partners Co-Leads
Emergent Tide is built on original research from the Tsinghua University School of Medicine team in the field of humoral immunity, developing novel therapeutics for inflammatory and autoimmune diseases against a first-in-class global target, addressing core challenges in the field and significant unmet clinical needs.
Qiming Weekly | Qiming Venture Partners Portfolio Funding and Updates Roundup Vol. 13, 2025
Following Qiming Venture Partners' portfolio companies' milestone moments with you
